Ampersand Capital Partners is a Wellesley, Massachusetts-based private equity firm founded in 1988, focused exclusively on healthcare, specifically life science tools, diagnostics, specialty pharma, and services. It invests in growth-stage companies with $5M–$50M in revenue. Ampersand's diagnostic and life science tools portfolio is highly relevant to neurotech, particularly in neurodiagnostics, neuroimaging tools, and lab-based diagnostics.

Its portfolio includes companies in diagnostic imaging, molecular diagnostics, and specialty pharma that touch neurological disease areas. Ampersand typically leads buyouts and growth equity investments in North America.